Ragene Rivera

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Linda T. Vahdat, Brian Pruitt, Carol J. Fabian et al. · Journal of Clinical Oncology · 2009 · 245 citations · Full text

Medicine, Oncology, Pharmacology +15

Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial

Adam Brufsky, Vicente Valero, B. Tiangco et al. · Breast Cancer Research and Treatment · 2012 · 127 citations

Medicine, Oncology, Pharmacology +12

Splicing profile by capture RNA-seq identifies pathogenic germline variants in tumor suppressor genes

Tyler Landrith, Bing Li, Ashley Cass et al. · npj Precision Oncology · 2020 · 87 citations · Full text

Life Sciences, Genetics, Oncology +17

Comparison of Menopausal Symptoms During the First Year of Adjuvant Therapy With Either Exemestane or Tamoxifen in Early Breast Cancer: Report of a Tamoxifen Exemestane Adjuvant Multicenter Trial Substudy

Stephen E. Jones, James Cantrell, Svetislava J. Vukelja et al. · Journal of Clinical Oncology · 2007 · 81 citations

Medicine, Oncology, Pharmacotherapy +17